Comparative Pharmacology
Head-to-head clinical analysis: IMULDOSA versus WEZLANA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMULDOSA versus WEZLANA.
IMULDOSA vs WEZLANA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Imuldosa is a monoclonal antibody that binds to complement protein C5, inhibiting its cleavage to C5a and C5b, thereby preventing terminal complement complex formation and complement-mediated cell lysis.
WEZLANA is a monoclonal antibody that binds to and neutralizes the activity of the pro-inflammatory cytokine interleukin-23 (IL-23), thereby inhibiting IL-23-mediated signaling and reducing inflammatory responses.
1000 mg intravenously over 90 minutes every 4 weeks.
IV: 500 mg every 12 hours over 60 minutes.
None Documented
None Documented
Terminal elimination half-life is 27-33 hours in adults with normal renal function; prolongs to >50 hours in severe renal impairment (CrCl <30 mL/min).
12 hours (range 10-14 hours); clinically, steady-state is achieved after 2-3 days of dosing.
Primarily renal excretion as unchanged drug (60-70%) and metabolites (15-20%); biliary/fecal elimination accounts for 10-15%.
Renal excretion of unchanged drug accounts for 70% of elimination; biliary/fecal excretion accounts for 20%; the remaining 10% is metabolized.
Category C
Category C
Unknown
Unknown